Skip to main content

Forbion Capital Partners — Portfolio

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

124
Companies
$12.0B
Total invested
$96.6M
Avg. check
16
Industries
Biotechnology 22Therapeutics 12Medical 9Life Science 8Health Care 8Pharmaceutical 6+10 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 1–24 of 124
OMass Therapeutics
October 2026

OMass Therapeutics is a drug discovery company exploiting novel mass spectrometry platforms to develop therapeutics.

Biotechnology · Oxford$310.0M Series C
Navigator Medicines
September 2026

Navigator Medicines operate as a biotech company.

Biotechnology · Scotch Plains$10.0M Venture - Series Unknown
Orbis Medicines
September 2026

Orbis Medicines is a novel macrocyclic chemistry and computational platform for oral macrocycle drug discovery.

Health Care · Frederiksberg$93.5M Corporate Round
Sling Therapeutics
September 2026

Sling Therapeutics develops pharmaceutical treatments for thyroid eye disease, a condition that can affect tissues surrounding the eyes.

Biopharma · Ann Arbor$123.0M Series C
Solstice Oncology
September 2026

Solstice Oncology develops immuno-oncology therapies focused on treating and preventing cancer through targeted approaches.

Biopharma · Boston$225.0M Series A
Dyne Therapeutics
July 2026

Dyne Therapeutics is a developer of targeted therapies intended for serious muscle diseases.

Biotechnology · Cambridge$375.1M Post-IPO Equity
RQ Bio
June 2026

RQ Bio is a biotechnology company that develops medicine based on potent broad-spectrum mAbs to provide immunity to viral infections.

Biotechnology · London$112.5M Series A
Memento Medicines
June 2026

Memento Medicines is a biotech developing bispecific antibody therapies for eye diseases.

Biotechnology · Chester$93.0M Series A
Mestag Therapeutics
March 2026

Mestag Therapeutics is a biotechnology company that develops new therapies for diseases using fibroblast technology.

Biotechnology · Cambridge$40.0M Series Unknown
Tropic Biosciences
March 2026

Tropic Biosciences is a pioneering leader in the development of novel high-performing commercial tropical crop varieties and traits.

Agriculture · London$105.0M Series C
Altesa
February 2026

Altesa is a clinical-stage biopharmaceutical company dedicated to accelerating the development of new treatments

Biotechnology · College Park$75.0M Series B
Beacon Therapeutics
January 2026

Beacon Therapeutics is a biotechnology company that develops treatments to preserve and restore vision for rare and prevalent eye diseases.

Biotechnology · Alachua$75.0M Series C
Corsera Health
January 2026

Corsera Health develops preventive RNA interference medicines that reduces cardiovascular disease risk before long-term damage occurs.

Biotechnology · Boston$80.0M Series A
Sidera Bio
December 2025

Sidera Bio harness human genetics, that helps in transformative medicines for patients.

Genetics · Copenhagen$109.0M Series A
Protego Biopharma
December 2025

Protego Biopharma is a biotechnology company that develops therapeutics that aim to correct diseases caused by protein misfolding.

Biopharma · San Diego$130.0M Series B
Gate Bioscience
November 2025

Gate Bioscience is a biotechnology company that specializes in a small molecule modality to treat biology’s intractable diseases.

Biotechnology · Brisbane$65.0M Series B
Braveheart Bio
November 2025

Braveheart Bio is a clinical-stage biotechnology company focused on developing precision therapies in the cardiovascular disease space.

Biotechnology · San Francisco$185.0M Series A
AAVantgarde Bio
November 2025

AAVantgarde Bio is a clinical-stage biotechnology company that develops gene therapies for inherited retinal disorders.

Biotechnology · Milano$141.0M Series B
PACT
October 2025

PACT designs Elegant materials produced in tune with the planet earth.

Biotechnology · Cambridge$21.1M Series A
Elevara Medicine
October 2025

Elevara is a clinical-stage firm working on innovative therapies to treat rheumatoid arthritis and other chronic inflammatory disorders.

Biotechnology · London$70.0M Series A
Sparrow Pharmaceuticals
September 2025

Sparrow Pharmaceuticals is a clinical-stage biopharmaceutical company developing treatments for disorders of corticosteroid excess.

Biopharma · Portland$95.0M Series B
Genomines
September 2025

Plant-based Mining Biotech

Biotechnology · Paris$45.0M Series A
Mosanna Therapeutics
June 2025

Mosanna Therapeutics develops a nasal spray for treating obstructive sleep apnea.

Biotechnology · Redwood City$80.0M Series A
Azafaros
May 2025

Azafaros aims at developing new therapeutic agents for the treatment of rare metabolic disorders.

Biotechnology · Leiden$146.7M Series B

Where Forbion Capital Partners invests

Biotechnology22
Therapeutics12
Medical9
Life Science8
Health Care8
Pharmaceutical6

About Forbion Capital Partners's portfolio

How many companies has Forbion Capital Partners invested in?▸

Forbion Capital Partners has invested in 124 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Forbion Capital Partners invest in?▸

Forbion Capital Partners's top investment sectors include Biotechnology, Therapeutics, Medical, Life Science, Health Care. The firm invests across 16 different industry categories.

What is Forbion Capital Partners's largest investment?▸

Among tracked funding rounds, Dyne Therapeutics received $375.1M in a Post-IPO Equity round. Forbion Capital Partners's total known invested capital is $12.0B.

What is the average investment size for Forbion Capital Partners?▸

Forbion Capital Partners's average investment size is $96.6M across its portfolio of 124 companies.

What are Forbion Capital Partners's most recent investments?▸

Recent Forbion Capital Partners portfolio additions include OMass Therapeutics, Navigator Medicines, Orbis Medicines, Sling Therapeutics, Solstice Oncology. These companies were founded in 2020 or later.

Reach the founders behind these 124 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →